FDA approval for GSK, Roche drugs could boost balance sheets

09/17/2008 | Reuters

The FDA is set to hand down by Friday its decisions on GlaxoSmithKline's Promacta and Roche Holding's Actemra, a move that may boost the drugmakers' market shares. Citigroup analysts estimated that by 2012, Promacta -- a drug to treat a rare blood disorder -- could generate $509.6 million, while Actemra -- a rheumatoid arthritis medicine -- could bring in $638 million.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Program Manager II
Tufts Health Plan/Network Health
Medford, MA
Director, Medicare Advantage/Medicare Part D Focus
Avalere Health
Washington, DC